Supreme Court Preserves Mail Access to Mifepristone

The JAMA study authors concluded that career FDA scientists acted with extreme caution and lacked ideological bias, repeatedly verifying that serious harms from the drug are "rare".

On May 14, 2026, the U.S. Supreme Court blocked a federal appeals court ruling to preserve nationwide mail-order and telehealth access to the abortion pill mifepristone while ongoing litigation plays out. The decision prevents immediate disruptions to medication abortion, which represents the most common method of ending pregnancies in the United States. 

Key Details of the Ruling

• The Action: The justices granted emergency requests from drug manufacturers Danco Laboratories and GenBioPro Inc..
• The Effect: It pauses a New Orleans-based 5th U.S. Circuit Court of Appeals order that would have mandated in-person doctor visits and halted mail distribution.
• The Timeline: Access is projected to remain fully uninterrupted into 2027 as the legal challenges proceed.
• The Dissents: Conservative Justices Clarence Thomas and Samuel Alito dissented from the one-paragraph order. Thomas argued the companies were seeking to preserve "lost profits from their criminal enterprise" under the 1873 Comstock Act.

Core Context of the Lawsuit
The emergency appeal directly stemmed from a lawsuit spearheaded by the state of Louisiana. Louisiana officials argued that the Food and Drug Administration's (FDA) policies allowing remote prescription delivery bypassed and undermined its strict state-level abortion ban.

This marks the second major instance of the Supreme Court intervening in mifepristone access. In 2024, the high court unanimously dismissed a separate challenge from anti-abortion medical groups, ruling that those plaintiffs lacked the legal standing required to sue the FDA.

Broader Political Landscape
The Supreme Court's intervention coincides with heightened friction surrounding federal abortion regulations:

• FDA Resignation: FDA Commissioner Marty Makary resigned earlier in the week following intense criticism from anti-abortion groups over the slow pace of a separate, ongoing federal review of mifepristone safety.
• Executive Review: That separate executive branch review was initiated under Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr..
• Telehealth Impact: Data shows that approximately one-quarter of all U.S. abortions are currently managed through telehealth, and nearly half of those patients reside in states with active abortion bans

Your browser does not support viewing this document. Click here to download the document.